THOR - WEEK CHART
Hi, today we are going to talk about Synthorx and its current landscape.
Synthorx shares are in evidence today as was unveiled that the company it's going to be acquired by the French multinational pharmaceutical company Sanofi for $68 per share (172% premium) in cash, totalizing a deal of $2.5 billion. In this season of Mergers and Acquisitions, the Sanofi move is based on its interest in build an oncology franchise, as the attention of the pharmaceutical over the sector growths.
Thank you for reading and leave your comments if you like.
To have access to our exclusive contents, join the Traders Heaven today! Link Below.
Disclaimer: All content of Golden Dragon has only educational and informational purposes, and never should be used or take it as financial advice.
Synthorx shares are in evidence today as was unveiled that the company it's going to be acquired by the French multinational pharmaceutical company Sanofi for $68 per share (172% premium) in cash, totalizing a deal of $2.5 billion. In this season of Mergers and Acquisitions, the Sanofi move is based on its interest in build an oncology franchise, as the attention of the pharmaceutical over the sector growths.
Thank you for reading and leave your comments if you like.
To have access to our exclusive contents, join the Traders Heaven today! Link Below.
Disclaimer: All content of Golden Dragon has only educational and informational purposes, and never should be used or take it as financial advice.
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.